Your browser is no longer supported. Please, upgrade your browser.
Settings
CALA Calithera Biosciences, Inc. daily Stock Chart
CALA [NASD]
Calithera Biosciences, Inc.
Index- P/E- EPS (ttm)-0.93 Insider Own6.38% Shs Outstand37.93M Perf Week-13.88%
Market Cap197.62M Forward P/E- EPS next Y-1.90 Insider Trans-0.06% Shs Float33.69M Perf Month8.54%
Income-33.30M PEG- EPS next Q-0.40 Inst Own73.80% Short Float2.40% Perf Quarter16.42%
Sales36.80M P/S5.37 EPS this Y56.70% Inst Trans7.78% Short Ratio2.23 Perf Half Y-12.07%
Book/sh4.10 P/B1.27 EPS next Y-50.80% ROA-18.10% Target Price12.25 Perf Year-69.53%
Cash/sh3.73 P/C1.40 EPS next 5Y- ROE-22.10% 52W Range4.05 - 17.95 Perf YTD-37.60%
Dividend- P/FCF- EPS past 5Y-21.40% ROI-19.80% 52W High-70.97% Beta2.23
Dividend %- Quick Ratio13.70 Sales past 5Y- Gross Margin- 52W Low28.64% ATR0.35
Employees73 Current Ratio13.70 Sales Q/Q134.20% Oper. Margin-96.90% RSI (14)45.75 Volatility6.63% 7.12%
OptionableYes Debt/Eq0.00 EPS Q/Q41.70% Profit Margin-90.70% Rel Volume1.35 Prev Close5.21
ShortableYes LT Debt/Eq0.00 EarningsNov 01 AMC Payout- Avg Volume362.55K Price5.21
Recom1.20 SMA20-5.07% SMA501.91% SMA200-12.85% Volume0 Change0.00%
Feb-16-18Upgrade Citigroup Neutral → Buy
Oct-05-17Initiated William Blair Outperform
Apr-03-17Resumed Leerink Partners Outperform
Mar-28-17Reiterated H.C. Wainwright Buy $10 → $14
Jan-24-17Upgrade Citigroup Sell → Neutral
Jan-05-17Initiated H.C. Wainwright Buy $9
Oct-25-16Initiated Citigroup Sell
Jul-24-15Initiated Citigroup Buy
Oct-15-18 08:55AM  Market Trends Toward New Normal in Nasdaq, Calithera Biosciences, Pinnacle West Capital, National Instruments, American Vanguard, and American Axle & Manufacturing Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-05-18 01:06PM  What Investors Should Know About Calithera Biosciences Incs (NASDAQ:CALA) Financial Strength Simply Wall St. +6.09%
07:01AM  Calithera Biosciences Highlights Breadth of Innovative Pipeline at R&D Day GlobeNewswire
07:00AM  Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE® (palbociclib) and talazoparib in Combination with CB-839 GlobeNewswire
Sep-26-18 08:00AM  Calithera Biosciences to Host R&D Day and Webcast on October 5, 2018 GlobeNewswire
Sep-24-18 08:00AM  Calithera Biosciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Rare Disease & Oncology Roundtable GlobeNewswire
Aug-29-18 07:05AM  Calithera Biosciences to Participate in the Citi 13th Annual Biotech Conference and the Wells Fargo Healthcare Conference GlobeNewswire
Aug-21-18 01:50PM  Edited Transcript of CALA earnings conference call or presentation 7-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Aug-14-18 08:15PM  Recent Analysis Shows Ellie Mae, Organovo, Calithera Biosciences, Whirlpool, Marathon Oil, and Infinera Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-07-18 07:40PM  Calithera (CALA) Reports Q2 Loss, Tops Revenue Estimates Zacks +5.95%
06:34PM  Calithera: 2Q Earnings Snapshot Associated Press
04:08PM  Calithera Biosciences Reports Second Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
03:00PM  Calithera Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 07:00AM  Calithera Biosciences to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018 GlobeNewswire
Jun-21-18 08:00AM  Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks ACCESSWIRE
Jun-06-18 05:01AM  Calithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June GlobeNewswire
Jun-04-18 08:01AM  Results from Phase 1 Study of CB-839 in Combination with Capecitabine in Advanced Solid Tumors to be Presented at the 2018 American Society of Clinical Oncology (ASCO) GlobeNewswire
May-16-18 07:30AM  Research Report Identifies Monster Beverage, Infinera, Zynga, Calithera Biosciences, Marathon Oil, and National Instruments with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
May-10-18 08:35PM  Calithera Biosciences Inc (NASDAQ:CALA): Is Breakeven Near? Simply Wall St.
05:56PM  Calithera: 1Q Earnings Snapshot Associated Press
04:05PM  Calithera Biosciences Reports First Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
Apr-25-18 04:51PM  Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales Zacks
04:03PM  Calithera Biosciences Announces CB-839 Abstracts Accepted for Presentation at ASCO 2018 GlobeNewswire
Apr-20-18 07:40AM  Blog Exposure - FDA Granted Fast Track Designation to Calithera Biosciences CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma Treatment ACCESSWIRE -5.43%
Apr-19-18 08:55AM  Calithera's Kidney Cancer Candidate Gets Fast Track Status Zacks
Apr-18-18 07:17AM  Calithera Biosciences stock surges on news of FDA fast track designation for kidney cancer treatment MarketWatch
07:01AM  Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of Patients with Advanced Renal Cell Carcinoma GlobeNewswire
Apr-13-18 08:02AM  Calithera Biosciences to Present New Preclinical Data for CB-839 at AACR Annual Meeting 2018 GlobeNewswire
Mar-23-18 08:00AM  Calithera to Present at Needham & Company 17th Annual Healthcare Conference GlobeNewswire
12:49AM  [$$] Dracen Pharma Grabs $36 Million Commitment from Deerfield The Wall Street Journal
Mar-10-18 08:06PM  Edited Transcript of CALA earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-08-18 07:31PM  Does Calithera Biosciences Incs (NASDAQ:CALA) Latest Financial Perfomance Look Strong? Simply Wall St.
06:53PM  Calithera reports 4Q loss Associated Press
04:05PM  Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
01:00PM  Calithera Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Mar-07-18 08:40AM  Why Calithera Biosciences (CALA) Might Surprise This Earnings Season Zacks +12.42%
Mar-06-18 08:01AM  Calithera to Present at Cowen & Company 38th Annual Health Care Conference GlobeNewswire
Mar-02-18 07:00AM  Calithera Biosciences to Report Fourth Quarter 2017 Financial Results on Thursday, March 8, 2018 GlobeNewswire
Feb-16-18 01:03PM  Here's Why Calithera Biosciences, Inc. Rose as Much as 25.2% Today Motley Fool +16.55%
Feb-09-18 05:00AM  Calithera to Participate in Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire
Feb-05-18 05:04PM  Results from Phase I Study of CB-839 in Combination with Everolimus or Cabozantinib in Patients with Renal Cell Carcinoma to be Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancer Symposium GlobeNewswire
Feb-02-18 08:25AM  Investor Expectations to Drive Momentum within Valero Energy Partners LP, Middlesex Water, ForeScout Technologies, Calithera Biosciences, eBay, and DexCom Discovering Underlying Factors of Influence GlobeNewswire
Jan-03-18 09:55AM  Edited Transcript of CALA earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
Dec-06-17 09:07AM  The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics Zacks
Dec-05-17 08:09AM  5 Top-Ranked Drug Stocks that are Broker Favorites Zacks
08:00AM  Updated Results from Phase I Study of CB-839 in Combination with Paclitaxel in Patients with Triple Negative Breast Cancer to be Presented at the 2017 San Antonio Breast Cancer Symposium GlobeNewswire
Nov-28-17 08:20AM  Report: Exploring Fundamental Drivers Behind Parsley Energy, Analog Devices, Exxon Mobil, Calithera Biosciences, Monster Beverage, and Marathon Petroleum New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-16-17 03:27PM  Calithera Sell-Off Unwarranted as Investors Ignore Positive Signal in Upcoming Breast Cancer Data SmarterAnalyst
Nov-08-17 01:43PM  Calithera Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : CALA-US : November 8, 2017 Capital Cube
Nov-07-17 10:03AM  Is Calithera Biosciences Inc (CALA) Undervalued? Simply Wall St.
08:01AM  Initial Results from Phase 2 Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting GlobeNewswire
Nov-06-17 08:05AM  Calithera Biosciences, Q3 Analysis, Analysts Target and Clinical Trials Review ACCESSWIRE
Nov-02-17 07:49AM  Calithera reports 3Q loss Associated Press +11.87%
07:30AM  Calithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Oct-26-17 08:48AM  Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics Zacks
Oct-25-17 08:36AM  5 Stocks in Focus on New Analyst Coverage Zacks
Oct-24-17 08:14AM  Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : October 24, 2017 Capital Cube
Oct-19-17 08:00AM  Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda GlobeNewswire
Oct-12-17 08:37AM  Surging Earnings Estimates Signal Good News for Calithera Biosciences (CALA) Zacks
Oct-11-17 08:25AM  Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences Zacks
Oct-05-17 11:32AM  Calithera Biosciences, Inc. Value Analysis (NASDAQ:CALA) : October 5, 2017 Capital Cube
Oct-04-17 08:27AM  Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : October 4, 2017 Capital Cube
Oct-03-17 08:00AM  Calithera Biosciences Announces Appointment of Sumita Ray as General Counsel GlobeNewswire
Sep-21-17 04:05PM  Calithera Biosciences Appoints Blake Wise to Board of Directors GlobeNewswire
Sep-20-17 08:00AM  Calithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Immuno-Oncology Roundtable GlobeNewswire
Sep-19-17 03:11PM  Calithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting GlobeNewswire
Sep-12-17 11:31AM  Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : September 12, 2017 Capital Cube
Sep-11-17 07:30PM  5 Ways To Play The Biotech Bull Market Oilprice.com
Sep-08-17 08:50AM  Earnings Estimates Moving Higher for Calithera Biosciences (CALA): Time to Buy? Zacks
Sep-04-17 04:42PM  Here Are 3 Strong Biotech Stocks In 2017 Forbes
Aug-30-17 08:00AM  Calithera Biosciences to Participate in the Citi 12th Annual Biotech Conference and the Wells Fargo Healthcare Conference GlobeNewswire
Aug-23-17 08:53AM  Calithera Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : CALA-US : August 23, 2017 Capital Cube
Aug-11-17 07:11PM  Edited Transcript of CALA earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents +15.35%
Aug-08-17 11:31PM  Calithera reports 2Q loss Associated Press
04:06PM  Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
10:00AM  Investor Network: Calithera Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 07:00AM  Calithera Biosciences Initiates a Randomized Phase 2 Combination Trial of CB-839 in Patients with Renal Cell Carcinoma GlobeNewswire
Aug-04-17 08:23PM  Calithera Biosciences, Inc. Value Analysis (NASDAQ:CALA) : August 5, 2017 Capital Cube
Aug-02-17 07:00AM  Calithera Biosciences to Report Second Quarter 2017 Financial Results on Tuesday, August 8, 2017 GlobeNewswire
Jul-24-17 09:30AM  Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : July 24, 2017 Capital Cube
Jul-20-17 09:02PM  3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now? Motley Fool
Jul-15-17 06:06AM  3 Stocks That Turned $1,000 Into at Least $2,017 in 12 Months Motley Fool
Jul-11-17 05:08PM  Five Scorching Hot Stocks Screaming Higher Zacks
Jul-10-17 08:48AM  Surging Earnings Estimates Signal Good News for Calithera Biosciences (CALA) Zacks
Jun-25-17 02:01PM  5 Best Biotech Stocks of 2017 So Far Motley Fool
Jun-16-17 08:41AM  Why Calithera Biosciences (CALA) Could Be Positioned for a Surge Zacks
Jun-14-17 07:00AM  Calithera Biosciences to Participate in the JMP Securities 2017 Life Sciences Conference GlobeNewswire
Jun-13-17 08:46AM  This Biotech Name Could Be Best In Breed For 2017 Benzinga
Jun-08-17 08:00AM  Today's Research Reports on Stocks to Watch: Calithera Biosciences and Cerus Corporation Accesswire -7.67%
Jun-07-17 09:45AM  How Calithera Biosciences Won Big With Its Cancer Treatment 24/7 Wall St. +5.84%
06:45AM  Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 for Treatment of Patients with Renal Cell Carcinoma GlobeNewswire
Jun-05-17 06:45AM  CB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-22-17 10:45AM  3 Under-the-radar Momentum Plays Investopedia
08:45AM  Calithera Biosciences (CALA) Jumps: Stock Moves 17% Higher Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Calithera Biosciences Accesswire
May-11-17 02:23PM  Edited Transcript of CALA earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-10-17 03:13PM  Here's Why Calithera Biosciences Stock Gained as Much as 16.4% Today Motley Fool +17.26%
06:59AM  Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma Business Wire
May-09-17 05:16PM  Calithera reports 1Q loss Associated Press
04:06PM  Calithera Biosciences Reports First Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839 in cell renal cell carcinoma. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Orford KeithSR. VP, CLINICAL DEVELOPMENTOct 15Sale6.053131,89410,314Oct 17 05:00 PM
Orford KeithSR. VP, CLINICAL DEVELOPMENTOct 11Sale6.001,2527,51210,627Oct 15 05:00 PM
Sjogren EricSR. VP, DRUG DISCOVERYApr 03Option Exercise0.4816,8108,06942,818Apr 05 04:06 PM
Molineaux SusanPRESIDENT AND CEOMar 02Option Exercise2.6426,99271,25944,860Mar 06 04:12 PM
Molineaux ChristopherSR. VP, DEVELOPMENTMar 02Option Exercise2.646,79817,94721,000Mar 06 04:08 PM
Wong StephanieSR VP, FINANCE AND SECRETARYFeb 23Option Exercise2.6410,00026,40015,000Feb 27 07:26 PM
Parlati FrancescoVP, RESEARCHFeb 20Option Exercise0.965,0954,89120,488Feb 22 04:05 PM
Molineaux ChristopherSR. VP, DEVELOPMENTDec 05Option Exercise1.459,20213,37011,702Dec 06 04:05 PM
Molineaux SusanPRESIDENT AND CEODec 05Option Exercise1.6512,86821,25715,368Dec 06 04:05 PM